These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 8266533

  • 1. Management of cytomegalovirus infection in high-risk recipients after renal transplantation: prophylaxis by hyperimmunoglobulins or DHPG treatment?
    Tenschert W, Gonnermann D, Meyer-Moldenhauer WH, Cremaschi L, Huland H.
    Transplant Proc; 1993 Dec; 25(6):3256-8. PubMed ID: 8266533
    [No Abstract] [Full Text] [Related]

  • 2. Incidence and therapy of cytomegalovirus disease after liver transplantation.
    Wiens M, Lefèbre B, Blumhardt G, Schmidt CA, Lohmann R, Neuhaus P.
    Transplant Proc; 1993 Apr; 25(2):1985-6. PubMed ID: 8385829
    [No Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus infection and prophylaxis in heart transplantation.
    Laske A, Gallino A, Carrel T, Niederhäuser U, von Segesser LK, Turina MI.
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1427-8. PubMed ID: 8382870
    [No Abstract] [Full Text] [Related]

  • 4. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Feb; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 5. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M, Ruthazer R, Freeman R, Bloom J, Fitzmaurice S, Fairchild R, Angelis M, Cooper J, Barefoot L, Rohrer R, Snydman DR.
    Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Dec; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

  • 8. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [Abstract] [Full Text] [Related]

  • 9. Cytomegalovirus infection in kidney transplantation: prophylaxis and management.
    Bulinski P, Toledo-Pereyra LH, Dalal S, Hernandez G.
    Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286
    [No Abstract] [Full Text] [Related]

  • 10. Ganciclovir in cytomegalovirus prophylaxis in high-risk pediatric renal transplant recipients.
    Prokurat S, Drabik E, Grenda R, Vogt E.
    Transplant Proc; 1993 Aug; 25(4):2577. PubMed ID: 8395104
    [No Abstract] [Full Text] [Related]

  • 11. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
    Nafar M, Pezeshki ML, Farrokhi F, Einollahi B, Pour-Reza-Gholi F, Firouzan A, Farhangi S.
    Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir.
    Prian GW, Koep LJ.
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977
    [No Abstract] [Full Text] [Related]

  • 14. A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y.
    J Antimicrob Chemother; 2005 Mar; 55(3):391-4. PubMed ID: 15705636
    [Abstract] [Full Text] [Related]

  • 15. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
    Ruttmann E, Geltner C, Bucher B, Ulmer H, Höfer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, Müller LC.
    Transplantation; 2006 May 27; 81(10):1415-20. PubMed ID: 16732179
    [Abstract] [Full Text] [Related]

  • 16. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T, Opatrny K, Bouda M, Treska V, Jindra P, Svecova M.
    Transpl Int; 2002 Dec 27; 15(12):615-22. PubMed ID: 12478408
    [Abstract] [Full Text] [Related]

  • 17. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID, Syriopoulou VP, Chelioti H, Daikos GL, Stamatiades D, Kostakis A, Boletis JN.
    Clin Microbiol Infect; 2005 Sep 27; 11(9):736-43. PubMed ID: 16104989
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease.
    Conti DJ, Freed BM, Lempert N.
    Transplant Proc; 1993 Feb 27; 25(1 Pt 2):1421-2. PubMed ID: 8382867
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.